Drug Development Pipeline
AZD5634 is a compound designed to block the function of the sodium (Na+) channel found in the lungs. These channels move sodium and water away from the airway surface. Blocking these channels may help maintain fluid within the airways to improve mucus clearance.
A phase 1b study of AZD5634 in adults with CF found that a single dose of inhaled AZD5634 did not have a significant impact on mucociliary clearance when compared with placebo. No further development in CF is planned at this time.
This program is sponsored by AstraZeneca. This program was conducted within the Therapeutics Development Network (TDN).
Recent AZD5634 Studies
Completed with Results
Phase 1b study of inhaled AZD5634 in adults with CF (AstraZeneca D6600C00002)
Sign up for clinical trial alerts
Get email updates about clinical trials that matter to you.
Explore clinical trials
Be a part of the movement transforming the future of cystic fibrosis treatment.Learn More